Board
Screen
Heat
Cal
Watch
News
Blog
TV
Home
/
RIGL
Home
/
RIGL

NASDAQ
$51.29
$51.29

Overview

Price performance
Low
$49.23
High
$51.74
After hours. Last updated: Nov 4, 2026, 9:00 PM UTC
$
51.29
2.43 (4.97%)
Average, 50 days
$47.86
$37.27
Open
$50.57
Previous close
$48.86
52-week high
$52.61
Oct 30, 2026 (6 days ago)
52-week low
$24.95
Mar 19, 2026 (8 months ago)
105.57%

Valuation & Estimates

Earnings

Financials

Insider Trading

Peer Analysis

Insights & Activity

Market Cap
958.09M
Volume
274 130
Total Return (3M)
32.53%
Total Return (1Y)
80.73%
8.44
Sector
Healthcare
Links
Tags
Healthcare
Biotechnology
NASDAQ
US
Website
rigel.com
About
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor, which is being advanced to Phase 1b study for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center (MDACC) for the development of olutasidenib in AML and other hematologic cancers with IDH1mutations; and the Collaborative Network for Neuro-Oncology Clinical Trial (CONNECT) to conduct a Phase 2 clinical trial to evaluate olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.

Frequently asked questions

RIGL · Rigel Pharmaceuticals, Inc.

01What is Rigel Pharmaceuticals, Inc. stock price today?

The current price of RIGL is $51.29 — it has increased by 4.97% since the previous close. Data as of Nov 4, 2026.

02Is Rigel Pharmaceuticals, Inc. stock price growing?

RIGL is down 0.98% over the past week, up 8.78% over the past month and up 80.73% over the past year. The price is above its 200-day moving average of $37.27.

03What is Rigel Pharmaceuticals, Inc. market cap?

Rigel Pharmaceuticals, Inc. has a market capitalization of $958.09M. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.

04Does Rigel Pharmaceuticals, Inc. pay dividends?

Rigel Pharmaceuticals, Inc. has not paid any dividends over the past year.

05How volatile is RIGL stock?

In the latest trading session RIGL moved between $49.23 and $51.74, a range of 4.90% of its current price.

06What are RIGL stock 52-week high and low?

Over the past 52 weeks RIGL has traded between $24.95 and $52.61. The current price is 2.51% below its 52-week high.

Figures as of Nov 4, 2026. This information is provided for general purposes only and is not investment advice.